Married at First Sight (American TV series)

DELFI Diagnostics Presents Additional Promising Proof-of-Concept Data on its Monitoring Program at AACR 2023

Retrieved on: 
Tuesday, April 18, 2023

The data were presented at the American Association for Cancer Research (AACR) 2023 Annual Meeting and builds on earlier studies showing the potential of using DELFI's technology for treatment monitoring.

Key Points: 
  • The data were presented at the American Association for Cancer Research (AACR) 2023 Annual Meeting and builds on earlier studies showing the potential of using DELFI's technology for treatment monitoring.
  • The study builds on prior work demonstrating the potential of the DELFI platform to monitor patients with metastatic cancer undergoing treatment with immunotherapy.
  • Also at AACR, DELFI and other researchers using the DELFI platform presented data describing the platform's strong performance in a training set that will be used to develop DELFI's first lung cancer screening product.
  • Researchers also shared promising initial data on the DELFI platform's ability to detect early stage ovarian cancer.

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022

Retrieved on: 
Friday, June 10, 2022

SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “company”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).

Key Points: 
  • (Imago or the company) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).
  • The data were presented in a poster session during the 30th European Hematology Association Annual Meeting and Congress (EHA), taking place 9-12 June 2022.
  • The potential of bomedemstat to be a unique and differentiated monotherapy for patients living with advanced myelofibrosis is underscored by the data presented at EHA today, saidHugh Young Rienhoff, Jr., M.D., CEO of Imago.
  • Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia ( NCT04254978 ) and myelofibrosis ( NCT03136185 ).

Canadian Pilot lands at MUI airstrip in rural PNG for the first time in 25 years

Retrieved on: 
Friday, January 14, 2022

In late 2021, there were many happy faces when Alberta native, MAF pilot Ryan Cole, did a test landing at the Mui airstrip in Papua New Guinea.

Key Points: 
  • In late 2021, there were many happy faces when Alberta native, MAF pilot Ryan Cole, did a test landing at the Mui airstrip in Papua New Guinea.
  • Due to the serious repairs needed, it had been almost 25 years since the airstrip has been used.
  • The surrounding communities combined efforts on this immense undertaking, working to restore it and get it up to standards.
  • Airstrips in remote locations like Mui provide access to medical evacuations for sick or injured people who may otherwise not survive their injury or illness.

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021

Retrieved on: 
Saturday, December 11, 2021

(Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).

Key Points: 
  • (Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).
  • The data were presented in an oral session during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021.
  • Previously, a Phase 2 data set with a cut-off date of May 17, 2021 was presented at the European Hematology Association 2021 Virtual Congress.
  • Todays ASH 2021 data further demonstrates the potential of bomedemstat as a unique and differentiated treatment option for patients living with advanced myelofibrosis, said Wan-Jen Hong, M.D., CMO, Imago BioSciences.